The Cigna Group stock: Piper Sandler cuts target to 360 dollars

The Cigna Group stock faces a new analyst signal after Piper Sandler lowered its price target while retaining an Overweight rating. The change adds a valuation reference to the companys recently raised 2026 earnings outlook.

According to MarketBeat, Piper Sandler reduced its target from 370 US dollars to 360 US dollars in a note issued Thursday. The brokerage maintained its Overweight view. MarketBeat reported a consensus rating of Moderate Buy and a consensus price target of 340.30 US dollars.

Quarterly growth remains uneven

The Cigna Group reported third-quarter revenue of 73.7 billion US dollars, up 6 percent from the prior-year period. Adjusted earnings per share rose to 7.98 US dollars from 7.83 US dollars, while reported net income declined because the year-earlier quarter included an after-tax gain on a business sale.

Operating trends differed across the companys businesses. Cigna Healthcare delivered stronger adjusted earnings, while Evernorths Pharmacy Benefit Services business faced pressure from client contract renewals and strategic investment. The company kept its 2026 adjusted income-from-operations outlook at a minimum of 30.60 US dollars per share.

Stock context for investors

The Cigna Group stock traded at 269.90 euros on Lang & Schwarz at 16:08 CET on Thursday, November 12, 2026.

Broader U.S. equities can be followed in the S&P 500 market overview.

Investors will continue to watch pharmacy benefit execution, medical-cost trends and the planned January 2027 exit from the Individual and Family Plans medical business. More news and analyses on The Cigna Group stock.